INTRODUCTION {#s1}
============

Precision medicine has rapidly moved to the forefront of cancer research by the application and evaluation of a broad range of molecular biomarkers. Most biomarker research in cancer focus on quantifying genetic alterations within the tumor and tumor cells. Liquid biopsies are increasingly tested as novel cancer biomarkers by evaluating the so-called 'tumor circulome' consisting of circulating tumor nucleic acids (ctDNA and ctRNA), circulating tumor cells (CTCs), and tumor extracellular vesicles \[[@R1], [@R2]\]. However, the potential of evaluating circulating proteins derived from the tumor microenvironment as novel liquid biopsies is undervalued.

Post-translational modifications (PTMs) of proteins can be a result of specific physiological and pathophysiological processes and can therefore, when identified, be used as disease specific markers. PTMs have been shown to reveal so called neoepitopes which, when targeted, have shown high potential as diagnostic and prognostic biomarkers in various cancer diseases \[[@R3]--[@R9]\]. Examples of PTMs are cross-linking of protein chains, hydroxylation of prolines, protease-generated fragments creating free ends, glycosylation, sumoylation, O'glcNAc and citrullination \[[@R10]--[@R15]\].

Vimentin, a protein which is a target of many PTMs including sumoylation, O'glcNAc and citrullination has recently gained attention due to its involvement in cancer \[[@R16]--[@R19]\]. Vimentin is an intermediate filament and its main role is to support cellular architecture and integrity. Besides being a structural protein, vimentin has many roles within cell differentiation and division, cell motility, migration, adhesion and cell death \[[@R16], [@R20]--[@R28]\]. Vimentin is upregulated in various cancer diseases including malignant melanoma, prostate, breast, gastro-intestinal and lung cancer \[[@R29]--[@R35]\]. In addition, vimentin is used as a canonical marker of epithelial-to-mesenchymal transition (EMT) and cancer-associated fibroblasts (CAFs) \[[@R36]--[@R39]\]. Originally it was thought that vimentin only had intracellular roles, however it is now appreciated that vimentin is also found extracellularly. The data concerning the function of extracellular vimentin are very limited. In the inflammatory setting, extracellular vimentin has been associated with various inflammatory states in different organs such as lupus erythematosus, pulmonary sarcoidosis, idiopathic pulmonary fibrosis and atherosclerosis \[[@R40]--[@R43]\]. In the vascular setting, extracellular vimentin has shown to be important in blood clotting via its contribution to Von Willebrand's factor string formation \[[@R44]\]. Furthermore, in wound healing, extracellular vimentin plays a role in the transition of mesenchymal cells to myofibroblasts, and in mice with spinal cord injury, vimentin induces axonal growth and increases motor function \[[@R45]--[@R47]\]. Finally, in the oncology setting, extracellular vimentin has been evaluated in patients with Sezary syndrome, malignant melanoma and lung cancer. Interestingly, in patients with malignant pleural mesothelioma vimentin correlates with disease state \[[@R8], [@R30], [@R48], [@R49]\]. Thus, the relevance of extracellular vimentin is rather unclear and must be further investigated.

During tumor development and progression extracellular vimentin may be a target of PTMs such as proteolytic cleavage by matrix metalloproteases (MMPs) overexpressed in the tumor microenvironment as well as citrullinations \[[@R16], [@R20], [@R50], [@R51]\]. Citrullination is the process in which arginine residues are modified into citrulline in a Ca^2+^ dependent conversion mediated by peptidyl arginine deiminase enzymes, which are often present during inflammatory states \[[@R52]--[@R55]\]. Interestingly, citrullinated vimentin has been found elevated in serum from lung cancer patients supporting a rationale for targeting vimentin as a liquid biopsy biomarker in this disease \[[@R30]\]. However, citrullinated vimentin is also highly elevated in patients with various inflammatory diseases \[[@R56]--[@R60]\]. To further evaluate the association between vimentin processing/PTMs and lung pathology we measured MMP-degraded citrullinated vimentin (VICM) and the non-citrullinated counterpart (VIM) in serum from two independent cohorts of patients with non-small cell lung cancer (NSCLC), a cohort of patients with chronic obstructive pulmonary disease (COPD) and healthy controls.

RESULTS {#s2}
=======

Technical evaluation of the VIM assay {#s2_1}
-------------------------------------

The specificity of the VIM assay was evaluated by analyzing the reactivity towards the selection peptide (RLRSSVPGVR), an elongated version of the selection peptide (RLRSSVPGVRL), a truncated version of the selection peptide (RLRSSVPGV), a nonsense selection peptide (LLARDFEKNY), a nonsense biotinylated coating peptide (LLARDFEKNY-biotin) and a citrullinated version of vimentin in which arginine is replaced with citrulline (RLRSSVPGV-Citrulline). The antibody only showed reactivity towards the selection peptide with a dose-dependent signal inhibition, suggesting specificity of the antibody towards the selection peptide ([Figure 1A](#F1){ref-type="fig"}).

![Specificity test of the MMP-degraded non-citrullinated vimentin (VIM) assay.\
(**A**) The reactivity of the VIM antibody was tested against the selection peptide (RLRSSVPGVR), elongated peptide (RLRSSVPGVRL), truncated peptide (RLRSSVPGV), nonsense peptide (LLARDFEKNY), nonsense biotinylated peptide (LLARDFEKNY-biotin) and the VICM peptide (RLRSSVPGV-Citrulline). %B/B0: B equals the OD at x ng/ml peptide and B0 equals the OD at 0 ng/ml peptide. (**B**) The reactivity of the VIM antibody was tested against recombinant full length vimentin, recombinant full length vimentin cleaved with MMP2 and recombinant full length vimentin cleaved with MMP8.](oncotarget-10-6829-g001){#F1}

To further investigate the specificity of the VIM assay, and to ensure that the VIM antibody only detects vimentin fragments generated by MMP2 and MMP8, recombinant full-length vimentin was incubated with the two MMPs. The antibody only showed reactivity towards vimentin fragments cleaved by MMP2 and MMP8, and not the full-length protein, suggesting that the VIM antibody only recognizes vimentin fragments cleaved by the two proteases ([Figure 1B](#F1){ref-type="fig"}).

The overall technical performance of the VIM assay was investigated using the following tests; intra-inter assay variation, dilution recovery, freeze-thaw recovery, analyte stability and recovery in biotin, lipid and hemoglobin. The results are summarized in [Table 1](#T1){ref-type="table"}. The detection range was determined to 1--132 g/mL (corrected for pre-dilution). The intra-assay variation was 5% and inter-assay variation 11%, and hereby acceptable as the acceptance criterion is below 10 and 15% for the two, respectively. Mean dilution recovery for 1:2 prediluted serum samples was 106%. The serum analyte stability was evaluated by observing analyte recovery after 4 freeze-thaw cycles and analyte storage at 4--20°C for 2--48 hours, with an acceptance criterion of the recovery within 100% ±20%. Spiking of selection peptide in human serum resulted in 100% mean recovery, indicating that the assay response is accurate and not affected by sample matrix. Analyte recovery after freeze-thaw cycles was 94%. Recovery of analyte stored at 4°C for 2--48 hours was 103--116%. Recovery of analyte stored at 20°C for 2--24 hours was 107--80%, thus recovery for analyte stored at 20°C for more than 24 hours could not be reached. This indicates that the analyte is stable up to 48 hours when stored at 4°C, however upon analysis the analyte should not be stored at 20°C for more than 24 hours. With the acceptance criterion at 100% ±20%, there was no detectable interference from biotin, lipid and hemoglobin with recoveries ranging from 87--114%.

###### Technical validation of the MMP-degraded non-citrullinated vimentin (VIM) assay

  Technical validation step                          Results
  -------------------------------------------------- --------------
  Detection Range                                    1--132 ng/mL
  Intra-assay variation                              5%
  Inter-assay variation                              11%
  Dilution recovery in serum                         106%
  Freeze-thaw recovery in serum                      94%
  Spiking Recovery                                   100%
  Analyte stability range in serum 4°C, 2 h--48 h    103--116%
  Analyte stability range in serum 20°C, 2 h--24 h   107--80%
  Interference:                                      
   Recovery in Biotin low/high                       108%/114%
   Recovery in Lipid low/high                        87%/92%
   Recovery in Haemoglobin low/high                  96%/99%

Percentages are reported as means.

Evaluation of VIM in serum from patients with solid tumors {#s2_2}
----------------------------------------------------------

To validate clinical relevance of the VIM assay, it was measured in serum from patients with different solid tumors (colon, lung, melanoma, ovary, prostate, stomach, breast and pancreas) and healthy controls. VIM was highly elevated in all indications suggesting that VIM is relevant in solid tumors (Supplementary Figure 1).

Serum VIM and VICM in NSCLC compared to healthy controls and patients with COPD {#s2_3}
-------------------------------------------------------------------------------

VIM and VICM were measured in serum samples from patients with NSCLC (stage I--IV) and healthy controls. The assays were measured in serum from two independent groups of patients with stage I--IV NSCLC (cohort 2 and 3). The two cohorts were measured at two different time points to validate biomarker levels in two independent cohorts. In cohort 2, consisting of 40 NSCLC stage I--IV patients and 20 controls VIM was significantly increased in NSCLC compared to controls (*p* = 0.003) ([Figure 2A](#F2){ref-type="fig"}). Interestingly, VICM was only slightly elevated with no statistical significance (*p* = 0.07) ([Figure 2B](#F2){ref-type="fig"}). In cohort 3, consisting of 60 NSCLC stage III-IV patients and 47 controls, both VIM and VICM were significantly elevated in NSCLC compared to controls (VIM: *p* \< 0.0001, VICM: *p* \< 0.0001) ([Figure 2C](#F2){ref-type="fig"}--[2D](#F2){ref-type="fig"}).

![Clinical evaluation of MMP-degraded vimentin (VIM) and MMP-degraded and citrullinated vimentin (VICM) in patients with non-small cell lung cancer (NSCLC).\
Levels of VIM and VICM in serum were evaluated in two independent cohorts of patients with NSCLC and healthy controls. VIM and VICM levels were compared to each other using the nonparametric Mann-Whitney test. Significance level: *p* \< 0.05. (**A**) Evaluation of VIM in cohort 2. (**B**) Evaluation of VICM in cohort 2. (**C**) Evaluation of VIM in cohort 3. (**D**) Evaluation of VICM in cohort 3.](oncotarget-10-6829-g002){#F2}

Next, we wanted to investigate VIM and VICM serum levels in a small cohort of COPD patients (*n* = 10), as VICM has shown to be of high relevance in inflammatory diseases \[[@R57], [@R58]\]. COPD is a chronic inflammatory lung disease which causes obstruction of the airways. Interestingly, there was no difference in serum VIM levels between COPD patients and controls (*p* = 0.12) ([Figure 3A](#F3){ref-type="fig"}). However, VICM was highly elevated in this cohort (*p* \< 0.0001) ([Figure 3B](#F3){ref-type="fig"}), suggesting that the two biomarkers are a measure of different pathophysiological phenomena.

![Clinical evaluation of MMP-degraded vimentin (VIM) and MMP-degraded and citrullinated vimentin (VICM) in chronic obstructive pulmonary disease (COPD).\
Levels of VIM and VICM in serum were evaluated in patients with COPD and healthy controls. VIM and VICM levels were compared to each other using the nonparametric Mann-Whitney test. Significance level: *p* \< 0.05. (**A**) Evaluation of VIM in COPD. (**B**) Evaluation of VICM in COPD.](oncotarget-10-6829-g003){#F3}

VIM and VICM vs. NSCLC stage {#s2_4}
----------------------------

The phenotypic distinctions observed between the two biomarkers led us to assess VIM and VICM in different stages of NSCLC. All NSCLC patients, including cohort 2 and cohort 3, were combined and stratified into their respective stages. There was a significant difference of VIM levels between stages of NSCLC (one-way ANOVA *p* = 0.01) ([Figure 4A](#F4){ref-type="fig"}). When combining stage I--II and stage III--IV, VIM was significantly elevated in late stages of NSCLC compared to early stages (*p* = 0.001) ([Figure 4C](#F4){ref-type="fig"}). In contrast, there was no difference in VICM levels between stages of NSCLC (stage I--IV: one-way ANOVA *p* = 0.28, stage I-II vs. stage III--IV: *p* = 0.24) ([Figure 4B](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}).

![Clinical evaluation of MMP-degraded vimentin (VIM) and MMP-degraded and citrullinated vimentin (VICM) in patients with non-small cell lung cancer (NSCLC) according to TNM disease stage.\
Levels of VIM and VICM in serum were evaluated in the two groups of patients with NSCLC stratified according to TNM disease stage I, II, III, IV (**A** and **B**) and I--II vs. III--IV (**C** and **D**). VIM and VICM levels were compared to each other using a one-way ANOVA with Kruskal-Wallis test (A and B) and the nonparametric Mann-Whitney test (C and D). Significance level: *p \<* 0.05.](oncotarget-10-6829-g004){#F4}

Correlation between VIM and VICM {#s2_5}
--------------------------------

To evaluate the extent to which the two variables were linearly related, VIM and VICM were compared pairwise and evaluated with Pearson's correlation coefficient. The analysis included both the healthy controls, COPD and cancer patients. No correlation between VIM and VICM serum levels was seen (r = --0.03 *p* = 0.67) ([Figure 5](#F5){ref-type="fig"}), emphasizing that the two biomarkers might be a measure of two different pathophysiological events.

![Correlation between MMP-degraded vimentin (VIM) and MMP-degraded and citrullinated vimentin (VICM).\
Levels of VIM and VICM in serum from patients with non-small cell lung cancer, chronic obstructive pulmonary disease and healthy controls where compared pairwise and evaluated by the Pearson correlation coefficient (r).](oncotarget-10-6829-g005){#F5}

Ability of VIM and VICM to discriminate between NSCLC, COPD and controls (diagnostic power) {#s2_6}
-------------------------------------------------------------------------------------------

To investigate the ability of VIM and VICM to discriminate between NSCLC, COPD and controls, the diagnostic power of VIM and VICM was calculated. The diagnostic power was based on the area under the receiver operating characteristics (AUROC) and by comparing NSCLC vs. controls, COPD vs. controls and NSCLCL vs. COPD. When compared head to head, VIM was superior to VICM in terms of separating NSLCL from controls (VIM: AUROC 95%, *p* \< 0.0001, VICM: AUROC 89%, *p* \< 0.0001) ([Figure 6A](#F6){ref-type="fig"}--[6B](#F6){ref-type="fig"}) and in separating NSCLC from patients with COPD (VIM: AUROC 97%, *p* \< 0.0001, VICM: AUROC 92%, *p* \< 0.0001) albeit the low n ([Figure 6E](#F6){ref-type="fig"}--[6F](#F6){ref-type="fig"}). However, VICM was superior to VIM in separating patients with COPD from controls (VIM: AUROC 70%, *p* = 0.1, VICM: AUROC 100%, *p* \< 0.0001) ([Figure 6C](#F6){ref-type="fig"}--[6D](#F6){ref-type="fig"}).

![Diagnostic power of MMP-degraded vimentin (VIM) and MMP-degraded and citrullinated vimentin (VICM) for separating non-small cell lung cancer (NSCLC) and chronic obstructive pulmonary disease (COPD) from healthy controls.\
The diagnostic power of VIM and VICM to discriminate between NSCLC vs. healthy controls (**A--B**), COPD vs. controls (**C--D**) and NSCLC vs. COPD (**E--F**) were calculated using the area under the receiver operating characteristics curve (AUROC).](oncotarget-10-6829-g006){#F6}

DISCUSSION AND CONCLUSIONS {#s3}
==========================

In this study, we evaluated the association of two different PTMs of vimentin, VICM and VIM, in patients with NSCLC, COPD and controls. To our knowledge, this is the first study to suggest that the involvement of vimentin in two distinct pathologies, even within the same organ, might be reflected by specific PTMs. We observed increased serum levels of VIM measured in two independent groups of patients with NSCLC. In addition, the increased levels were even more pronounced in late stages of NSCLC. In contrast, VIM was not increased in serum from COPD patients. When measuring VICM, we observed elevated levels in NSCLC patients but no association with stage of disease. Moreover, VICM was elevated in patients with COPD. Hence, these findings support previously published data which show that vimentin is elevated in COPD and NSCLC \[[@R30], [@R61]\].

Our findings indicate that two MMP degraded vimentin fragments can measure two distinct pathophysiological events. And as supported by previous research, we observed that VIM is potentially more associated with tumorigenesis and VICM is potentially more associated with general chronic inflammation \[[@R30], [@R56]--[@R59], [@R62]\].

Elevated levels of vimentin are reported for numerous solid tumor types suggesting a role for vimentin in cancer pathologies \[[@R29]--[@R35]\]. These data support our findings which show that VIM is increased in serum from patients with breast, colon, lung, melanoma, ovary, pancreas and stomach cancer. In addition, accumulating evidence shows that vimentin plays a role especially in the progression of NSCLC, which is also in line with our results \[[@R16], [@R20], [@R63]\] showing that VIM and VICM are increased in patients with NSCLC compared to healthy controls.

Several studies have shown a contributing role of vimentin in tumor progression and late stages of NSCLC which are characterized by invasion of lymph nodes, chest wall and metastasis to other parts of the body \[[@R64]\]. Vimentin predicts metastases and poor overall survival in NSCLC and the expression of vimentin is associated with tumor cell invasion \[[@R65]--[@R67]\]. Vimentin is a regulator of EMT which results in tumor cells being able to invade and metastasize neighboring tissue \[[@R34], [@R35], [@R38], [@R39], [@R63]\]. Furthermore, the expression of vimentin in CAFs is a requirement in the progression of early stage lung adenocarcinoma \[[@R35]\]. Thus, it can be speculated if these events can be explanations for the increased levels of VIM in late stages of NSCLC. Interestingly, VICM was not elevated in late stages of NSCLC further supporting that VIM is associated with tumor biology and potentially reflects tumor burden.

It has been shown that citrullinated proteins are commonly present in inflamed tissue suggesting that this process is inflammation-dependent \[[@R53]\]. PTMs can regulate the function of vimentin and it can be speculated if they can be a function of a specific pathology. Our results showed that VIM and VICM did not correlate, again suggesting that the two biomarkers are a measure of distinct pathophysiological events. We have previously shown that VICM is highly elevated in inflammatory diseases such as rheumatoid arthritis, ankylosing spondylitis and Crohn's disease \[[@R56]--[@R59]\]. In addition, citrullinated vimentin has been shown to be present in lung tissue from patients with COPD \[[@R61]\]. These findings are in line with our results showing that serum VICM is elevated in patients with COPD. These results further support our hypothesis that VIM is associated with tumor progression, while VICM may be more reflective of common states of inflammation independent of tumor stage. However, it remains to be established whether the differences seen between groups are biologically relevant in terms of a significant pathological event.

The present study is limited by several factors. Firstly, albeit findings are validated in independent cohorts the sample size of patients is relatively small. Secondly, controls and patients in cohort 1, 3 and 4 are not obtained from the same vendor. Furthermore, patients and controls in these three cohorts are not gender, age and ethnicity matched which can have confounding effects. However, results from cohort 2, containing patients matched on gender, age and ethnicity, are similar to the results obtained in cohort 3. Thirdly, the study is limited by the cross-sectional study with limited availability of clinical and pathological characteristics. Hence, it would be desirable to study VIM and VICM in a larger longitudinal study with well described clinical and demographic characteristics.

In summary, in this study we measured VIM and VICM and found different expression patterns in serum from patients with NSCLC, COPD and healthy controls. Overall, VIM was superior to VICM in discriminating NSCLC patients from patients with COPD and healthy controls. In contrast, VICM was more associated with COPD patients than VIM. The findings demonstrate that specific PTMs of vimentin are highly relevant in different pathological settings and that targeting these modifications can have differential biomarker potential reflecting diverse disease states. Future investigations are warranted to fully understand the biomarker potential and underlying mechanisms of vimentin modifications.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Four patient cohorts were validated in this study. Cohort 1 was obtained from the commercial vendor Asterand Bioscience (Detroit, MI, USA) and included patients with different cancer indications; breast (*n* = 2), colon (*n* = 3), lung (*n* = 12), malignant melanoma (*n* = 6), ovarian (*n* = 8), pancreas (*n* = 4), prostate (*n* = 6) and stomach cancer (*n* = 7) and 19 controls (Valley BioMedical, VA, USA) and. Patients in cohort 2, 3 and 4 were obtained from the commercial vendor ProteoGenex (CA, USA) and controls from Valley BioMedical (VA, USA). Cohort 2 included 40 NSCLC patients (stage I--IV) and 20 controls. Cohort 3 included 60 NSCLC patients (stage III--IV) and 47 controls. Cohort 4 included 10 patients with COPD and 10 controls. Appropriate Institutional Review Board/Independent Ethical Committee approved sample collection and all subjects filed informed consent. Demographics and clinical profiles are shown in [Table 2](#T2){ref-type="table"}.

###### Patient demographics and clinical profiles

  Group                       No. of patients   Stage   Gender, (% females)   Age, median (range)   Race                       
  -------------- ------------ ----------------- ------- --------------------- --------------------- ------ ----- ------------- --------------
  **Cohort 1**                                                                                                                 
                 *Cancer*     48                \-      \-                    \-                    \-     56%   61 (30--82)   100% C
                 *Controls*   19                \-      \-                    \-                    \-     16%   37 (22--54)   16% C 84% B
  **Cohort 2**                                                                                                                 
                 *NSCLC*      40                10      10                    10                    10     50%   62 (60--65)   100% C
                 *Controls*   20                \-      \-                    \-                    \-     50%   61 (60--65)   100% C
  **Cohort 3**                                                                                                                 
                 *NSCLC*      60                \-      \-                    30                    30     43%   61 (58--78)   100% C
                 *Controls*   47                \-      \-                    \-                    \-     19%   33 (21--59)   21% C 79 % B
  **Cohort 4**                                                                                                                 
                 *COPD*       10                \-      \-                    \-                    \-     50%   54 (50--60)   100% C
                 *Controls*   10                \-      \-                    \-                    \-     20%   28 (22--46)   10% C 91% B

NSCLC, non-small cell lung cancer; COPD, chronic obstructive pulmonary disease; C, Caucasian; B, black.

Biomarker measurements {#s4_2}
----------------------

Levels of VICM in serum were measured according to manufactures instruction's (Nordic Bioscience A/S, Denmark). For technical evaluation of the VICM assay see \[[@R60]\]. VIM levels in serum were measured according to the procedures described below.

VIM assay development {#s4_3}
---------------------

### Antibody development {#s4_3_1}

The identification of the VIM fragment, antibody production and immunization have been described in detail by our group \[[@R60]\]. Briefly, human cartilage was digested with a range of proteases (MMP2, 3, 8, 9, 12 and 13) and the proteolyzed peptide products were identified by mass spectrometry. For antibody development, ten different vimentin fragments were selected for immunization. All relevant sequences were analyzed for homology and blasted for homology using the NPS@: network protein sequence analysis \[[@R68]\]. Monoclonal antibodies were raised in 6-week-old BALB/c mice \[[@R60]\].

The vimentin sequence RLRSSVPGVR immunization generated the best antibody in terms of native reactivity and stability and was chosen for assay development. The sequence located at amino acid position 69 and 78 was identified as being generated by MMP2 and MMP8. The antibody was tested against reactivity towards the selection peptide (RLRSSVPGVR), an elongated version of the selection peptide (RLRSSVPGVRL), a truncated version of the selection peptide (RLRSSVPGV), a nonsense peptide (LLARDFEKNY) and a citrullinated version of vimentin in which arginine is replaced with citrulline (RLRSSVPGV-Citrulline).

### VIM ELISA assay {#s4_3_2}

Optimal incubation timer, buffer, temperature and optimal ratio between the biotinylated peptide and antibody were determined. The competitive ELISA procedure was as follows: 96-well streptavidin-coated microtiter plates were coated with 100 ul of 1.5 ng/mL biotinylated peptide (Biotin-K-RLRSSVPGVR) dissolved in assay buffer (50 mM PBS-BTB, 8 g/L NaCl, pH 7.4) and incubated in darkness on a plate shaker (300 rpm) for 30 minutes 20°C. After washing the plates five times in washing buffer (20 mmol/L TRIS, 50 mmol/L NaCl, pH 7.2), 20 μL of sample (pre-diluted 1:2)/controls/selection peptide (RLRSSVPGVR) were added. Hundred μL of 16.7 ng/mL monoclonal antibody diluted in assay buffer was added, and the plates were incubated in darkness on a plate shaker for 20 hours at 4°C. After washing the plates five times, 130 ng/mL goat anti-mouse horseradish peroxidase (HRP)-conjugated IgG antibody (Thermo Scientific, Waltham, MA, USA) diluted in assay buffer was added to each well, and the plates were incubated in darkness on a plate shaker for 1 hour at 20°C. After washing the plates five times in washing buffer, 100 μL Tetramethylbenzidine (Kem-En-Tec Diagnostics, Taastrup, Denmark) was added and the plates were incubated in darkness on a plate shaker for 15 minutes at 20°C. The reaction was stopped using 100 μL of 1% sulfuric acid. The plates were analyzed in a VersaMax ELISA microplate reader at 450 nm with 650 nm as reference. A standard curve was plotted using a 4-parametric mathematical fit model, and data were analyzed using GraphPad Prism version 7 (GraphPad Software, Inc.).

### Technical evaluation {#s4_3_3}

To evaluate the technical performance of the VIM ELISA assay, the following validation tests were carried out: Intra-inter assay variation, linearity, lower limit of detection, upper limit of detection, analyte stability (freeze/thaw and storage) and interference. The inter-intra assay variation was determined based on ten independent runs on different days using five quality controls of known concentration covering the detection range. Three of the quality controls were serum samples and two were selection peptide diluted in buffer. The intra-assay variation was calculated as the mean coefficient of variance (CV%) within plates and the inter-assay variation was calculated as the mean CV% between the ten individual runs analyzed on different days.

### Cleavage of vimentin {#s4_3_4}

To test the specificity of the VIM antibody towards vimentin cleaved by MMP2 and MMP8, recombinant human vimentin (Novus Biologicals, CO, USA) was reconstituted to a final concentration of 1000 ug/mL in 4 mM HCl. MMP2 and 8 was added to the reconstituted vimentin 1:10 (2 µg protease and 20 µg vimentin) in MMP-buffer (50 mM Tris-HCl, 150 mM NaCl, 10 mM CaCl2, 10 µM ZnCl, 0.05%Brij35, pH 7.5). The solution was incubated at 37°C for 24 hours. Digestion of methyl transferrin was included as a positive control and MMP-buffer with only proteases was included as a negative control. The digestion was stopped by adding 1 µm EDTA to each vial. Vials were stored at --80°C until analysis. The activity of the proteases was confirmed by silver staining (SilverXpress^®^ Invitrogen, CA, USA) and Coomassie blue according to manufacturer's instructions (data not shown). The specificity of the VIM antibody towards digested vimentin was confirmed by the VIM ELISA assay. To assess the clinical relevance of the VIM assay VIM serum levels were measured in serum samples from a small cohort of patients with different cancer diseases (cohort 1).

### Clinical evaluation of VIM and VICM {#s4_3_5}

To compare VIM with VICM serum levels they were measured in two independent cohorts of patients with stage I-IV NSCLC and measured in a cohort of COPD patients and compared to healthy controls. VICM was measured according to manufactures instructions (Nordic Bioscience A/S, Denmark) (see also \[[@R60]\]). VIM was measured according to above procedure.

Statistical analysis {#s4_4}
--------------------

The nonparametric Mann-Whitney test was used to compare biomarker levels between patients and controls. To evaluate the difference between different stages of NSCLC a one-way ANOVA with Kruskal-Wallis test was used. The diagnostic accuracy of VIM and VICM was obtained from the AUROC curve. Pearson's correlation coefficient was used to calculate the correlation between VIM and VICM. A *p*-value of *P* \< 0.05 was considered statistically significant. Graph design and statistical analyses were performed using GraphPad Prism version 7 (GraphPad Software, Inc.) and MedCalc version 14 (MedCalc Software).
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